



Business Development
& Licensing at a Glance

Biopharmaceutical Industry

Brazil - 3

Pharma Meeting
Brazil & Latam

2021



Agreement between Pfizer – BioNTech and Eurofarma boosts Covid 19 vaccine production in Brazil

The signature of a letter of intent between Pfizer Inc. (NYSE: PFE), BioNTech SE (Nasdaq: BNTX) and Brazilian pharmaceutical company Eurofarma was announced today to produce and distribute Comirnaty, a mRNA vaccine against covid-19, in Latin America.

Upon the agreement, Eurofarma will now be part of a supply and distribution chain for this vaccine, together with more than twenty other companies spread across four continents. Production is expected to start in 2022, and tech-transfer, local development and equipment installation activities will begin immediately. The Brazilian company expects to produce 100 million doses per year.

Pfizer expects global vaccine sales to achieve US\$33.5 billion in 2021.

Albert Boula, Pfizer's CEO and President said that this agreement with Eurofarma should expand the global supply chain providing fair and equitable access to the vaccine. For Ugur Sahin, CEO and co-founder of BioNTech, this activity is a new step to empower people around the world to produce and distribute the vaccine with quality and dose manufacturing process assurance.

Maurizio Billi, President of Eurofarma, highlights that, close to its 50th anniversary, the company is proud to be able to employ its best resources in industrial, technology and quality capacity for this project with excellence, thus contributing to supply the Latin American market.

Would you like to explore business opportunities in the biopharma industry? Join Pharma Meeting Brazil & Latam®. Since 2008, the best business partnering in Brazil and Latam. More information at www.pharmameetingbrazil.com.br.